Metagenomi (NASDAQ:MGX) Now Covered by HC Wainwright

HC Wainwright started coverage on shares of Metagenomi (NASDAQ:MGX) in a report issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $10.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 47.06% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Metagenomi in a report on Tuesday, March 5th. They set an “overweight” rating and a $25.00 price target for the company. JPMorgan Chase & Co. downgraded Metagenomi from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $16.00 to $6.00 in a report on Thursday, May 2nd. Jefferies Financial Group started coverage on Metagenomi in a report on Tuesday, March 5th. They set a “buy” rating and a $23.00 price objective on the stock. TD Cowen started coverage on Metagenomi in a research note on Tuesday, March 5th. They set an “outperform” rating for the company. Finally, BMO Capital Markets began coverage on shares of Metagenomi in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $22.00 price target for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.83.

Metagenomi Trading Up 5.3 %

Metagenomi stock opened at $6.80 on Tuesday. Metagenomi has a one year low of $5.50 and a one year high of $12.74. The business’s 50 day moving average is $9.55.

Insider Transactions at Metagenomi

In related news, major shareholder Holdings A/S Novo acquired 800,000 shares of Metagenomi stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average price of $15.00 per share, with a total value of $12,000,000.00. Following the completion of the acquisition, the insider now directly owns 1,739,175 shares of the company’s stock, valued at approximately $26,087,625. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.